Atossa Therapeutics Earnings Estimate

Atossa Therapeutics Earnings per Share Projection vs Actual

About Atossa Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Atossa Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Atossa Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Atossa Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. ATOSSA THERAPEU operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 6 people.

Currently Active Assets on Macroaxis

Other Information on Investing in Atossa Stock

Atossa Therapeutics financial ratios help investors to determine whether Atossa Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Atossa with respect to the benefits of owning Atossa Therapeutics security.